Routine annual meeting filing with no material financial news. Monitor future equity grants for dilution, but no immediate trading catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 21 $29.19entry
- T+1 · 6mo ago −0.62%α −1.06% · $29.01
- T+5 · 6mo ago +2.95%α +1.35% · $30.05
- T+20 · 5mo ago +22.58%α +22.24% · $35.78
- T+60 · 3mo ago +45.43%α +41.13% · $42.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rigel Pharmaceuticals filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Shareholders approved amendments to the 2018 Equity Incentive Plan and 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares respectively, and ratified Ernst & Young as auditor. No director departures or officer changes occurred.
Key Facts
- Shareholders approved amendment to 2018 Equity Incentive Plan, adding 500,000 shares
- Shareholders approved amendment to 2000 Employee Stock Purchase Plan, adding 360,000 shares
- All three director nominees (Hannah, Moos, Rodriguez) were elected
- Say-on-pay and ratification of Ernst & Young as auditor passed
- No departures, appointments, or material financial disclosures
Financial Impact
No immediate financial impact; potential future dilution from ~860,000 newly authorized shares under equity plans
Risk Factors
- Potential future dilution from equity plan shares
- No forward guidance or operational updates provided
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000041 |
| Document: 0001034842-26-000041-index.html | 0001034842-26-000041 |
| Document: 0001034842-26-000041.txt | 0001034842-26-000041 |
Track record
12 reports on RIGL
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.02% at T+60 after the May 12, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
- Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
- Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
- May 20, 202625w ago 8-K Neutral 2/10 Viewing Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
- May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
- May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers